Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are considering NK cell therapy in Japan, it is natural to ask what you might feel afterward. Any medical treatment can cause reactions, and knowing what to look for helps you plan your travel, your work, and your follow-up with the doctors who already care for you. This article explains, in plain language, what temporary reactions have been described with NK cell therapy, why they may occur, and what to discuss with a physician before you decide.
In short, NK cell therapy uses your own cells, and serious side effects have rarely been reported, but mild and temporary reactions such as fever or fatigue can occur. No treatment is free of risk, and your own situation can only be assessed by a doctor at a consultation.
How NK cell therapy works, and why it matters for side effects
NK (natural killer) cells are a type of lymphocyte that circulates in the blood. They are part of the innate immune system and can detect and attack abnormal cells, including cancer cells and virus-infected cells, without waiting for instructions from other immune cells. Research suggests that NK cell activity can decline with age, stress, and the effects of cancer itself.
In NK cell therapy, a sample of your blood is collected through a standard blood draw. At a specialized cell processing facility, your NK cells are activated and expanded in culture. The cells are then returned to your body by intravenous (IV) infusion. Because the cells come from you, the therapy is described as autologous. This is one reason the risk of rejection is considered low compared with treatments that use another person’s cells. It does not mean the therapy carries no risk, and the effects of infusing a large number of activated cells are still being studied in clinical research.
Reactions that have been described: fever, fatigue, and others
The most commonly mentioned reactions are temporary. They tend to appear around the time of the infusion or within a short period afterward, and they usually relate to the immune system becoming more active. Reported examples include:
- Fever or a feeling of chills, sometimes similar to a mild cold.
- Tiredness or a general feeling of being unwell.
- Mild headache or muscle aches.
- Discomfort, redness, or bruising at the blood draw or infusion site.
How a person responds varies. Some people notice very little, while others feel tired for a day or two. Published studies of NK cell infusions have generally described treatment-related events as mild to moderate, but those studies differ in cell source, dose, and patient groups, so their findings should not be applied to every individual. Your doctor can explain which reactions are more relevant to your health condition and current medications.
Why your own medical background changes the picture
The same therapy can feel different from one person to the next. Factors that a physician may consider include your type of cancer, any surgery, chemotherapy, or radiation therapy you are receiving or have received, your general condition, other illnesses such as autoimmune or heart conditions, and the medicines you take. For example, some people are more sensitive to fever or fatigue when they are already in the middle of an intensive standard treatment.
NK cell therapy is generally positioned as something that can be considered alongside standard treatment such as surgery, chemotherapy, or radiation therapy, not as a replacement for them. If you are in treatment, it is important that your home oncologist and the Japanese clinic share information so that timing and symptoms can be understood together. Grand Green Osaka Umekita Clinic can coordinate with the medical institution providing your standard treatment when you wish.
When to contact a doctor after treatment
Mild reactions often settle by themselves, but you should not try to judge this alone. Before you leave the clinic, ask how to reach the medical team, and ask what to do if symptoms appear after you return home or to your hotel. Practical points that are worth discussing include:
- What temperature or symptom level should prompt you to call the clinic.
- Whether you can take over-the-counter fever or pain medicine, and which one is appropriate for you.
- Which symptoms need urgent care, such as difficulty breathing, a rash that spreads, or a fever that does not settle.
- How to explain the treatment to a local hospital if you need care while traveling.
- Whether a summary of your treatment can be provided for your doctor back home.
If you feel seriously unwell, seek emergency medical care first and tell the staff that you recently received a cell therapy infusion. Do not wait for a scheduled follow-up.
What to confirm at your consultation in Osaka
NK cell therapy at Grand Green Osaka Umekita Clinic is provided as a self-pay treatment, which means it is not covered by Japanese public health insurance. In Japan, therapies of this kind are provided under the Act on the Safety of Regenerative Medicine, based on a provision plan submitted to and accepted by the authorities. That framework is intended to manage cell handling and safety, but it does not guarantee any particular result for any patient.
At your consultation, ask the doctor to explain the possible risks and side effects in your case, the expected number of infusions and their schedule, the total cost and what it includes, and the limits of what the therapy can offer. It is reasonable to ask for these details in writing and to take time before deciding. You may also wish to bring recent test results and a treatment summary from your current doctor.
The clinic is located in Umeda, Osaka, and information pages are available for international patients, so you can review the process in your own language before you contact the team. Whether NK cell therapy is suitable for you is a decision to be made with a physician after a proper examination, together with your existing medical team.
If you have questions about what to expect after an infusion, writing them down before your visit is a simple way to make the most of your consultation.
- Temporary reactionsFever or fatigue may occur
- Ask your doctorYour risks depend on your condition
- Know who to callPlan contact before you leave
- Self-pay treatmentConfirm cost and risks first
This diagram is a conceptual summary of the article content
References
- PubMed: Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. (2026)
- PubMed: Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance. (2024)
- PubMed: Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. (2020)
- PubMed: CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. (2023)
- PubMed: A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. (2022)
- PMC: Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. (2013)
- PMC: Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. (2015)
- PMC: Purification and antibody-free ex-vivo expansion of peripheral blood-derived autologous natural killer cells: A Malaysian case series on patient safety and tolerability. (2026)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.